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Abstract: Percutaneous radiofrequency ablation (PRFA) of solid tumors is a minimally inva-
sive procedure used to treat primary or metastatic cancer lesions via needle targeted thermal
energy transfer. Some of the most common tumor lesions treated using PRFA include those
within the liver, lungs and kidneys. Additionally, bone, thyroid, and breast lesions can also be
treated. In most cases, this procedure is performed outside of the operating room in a specialized
radiology suite. As a result, the clinician must adapt in many cases to the speciﬁc environmental
issues attendant to providing anesthesia outside the operating room, including the lack of
availability of an anesthesia machine in some cases, and frequently a lack of adequate scavenging
and other specialized monitoring and equipment. At this time, routine practice and anesthetic
prescriptions for PRFA can vary widely, ranging from patients receiving local anesthesia alone,
to monitored anesthesia care, to regional anesthesia, to combined regional and general anesthe-
sia. The choice of anesthetic technique will depend on tumor location and practitioner experi-
ence. This review aims to summarize the current state of the art in terms of anesthetic techniques
for patients undergoing PRFA of solid tumors.
Keywords: anesthesia, conduction, deep sedation, conscious sedation, neoplasms,
radiofrequency ablation, radiography, interventional
Introduction
Percutaneous radiofrequency ablation (PRFA) of solid tumors is a minimally invasive
procedure intended to treat primary and/or metastatic solid tumors via thermal tissue
destruction as a result of targeted thermal energy deposition and coagulative necrosis.1,2
The procedure is performed using 14–21G partially insulated needle electrodes con-
nected to a radiofrequency generator. The electrode is usually expandable andmulti-tined
so that, when deployed and extended, it can treat lesions up to 5 cm in diameter. The area
of necrosis is dependent on the temperature achieved at the level of the tissue and the
duration of heating.1,2 Typically, tissue necrosis is achieved at a temperature of 60–100 °
C for 4–6mins, but in cases where thermal conduction into the lesion is slow, the duration
of application may need to increase to as much as 20–30 mins.1,2 With PRFA, the most
commonly treated lesions at this time are those within the liver, lung and kidney, but the
role of PRFA in other solid tumors appears to be expanding with applications now in
pancreatic, soft tissue, bone and thyroid neoplasms.1–3
From an anesthetic standpoint, the clinician’s goal, as always, must be to
alleviate or moderate procedural discomfort while also facilitating the performance
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of the procedure. In general, the two primary stimuli are
the initial skin puncture as well as the deeper pain asso-
ciated with thermal tissue necrosis. In some cases, espe-
cially with lesions of the liver and lung, patient
cooperation may actually help facilitate accurate lesion
and needle localization making monitored anesthesia care
(MAC) by itself or in combination with regional anesthe-
sia the technique of choice. In other cases, the patient may
not be able to tolerate the procedure without general
anesthesia. Unfortunately, because many patients with
these lesions have signiﬁcant comorbidities, they may
also not be ideal surgical candidates and may be at
increased risk of complications from general anesthesia
requiring the clinician to very carefully consider an anes-
thetic prescription which keeps beneﬁts and risks appro-
priately in balance. As a result, there is no overall
consensus on the best anesthetic approach to patients
undergoing PRFA. This review summarizes the current
state of the art for different anesthetic techniques used
for a patient undergoing PRFA of solid tumors.
Overview and Preoperative
Evaluation for PRFA Procedures
PRFA in many cases is performed under ultrasound guidance
but also can be performed using CTorMRI.1,2 As a result, this
procedure is commonly performed outside of the operating
room. In general terms, non-operating room anesthesia
(NORA) has become essential in the delivery of procedural
care in the modern era, as ever-increasing numbers of these
cases are performed outside of the operating room. While the
characteristics of these procedures vary, in many cases, these
invasive procedures require the utilization of anesthesia to
Figure 1 An overall workﬂow diagram of PRFA from the anesthesiologist’s point of view.
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provide the proceduralist with optimal conditions. To safely
provide NORA in remote locations, it is imperative that the
clinician perform a focused preoperative evaluation and make
adequate on-site preparations. In addition to making standard
airway and monitoring equipment available such as an appro-
priately sized supraglottic airway and end-tidal carbon dioxide
monitoring, the clinician must also have contingency plans in
place to deal with crisis management and post-procedure
recovery.
In most cases, a thorough pre-operative patient evaluation
should be performed; however, there are speciﬁc areas that
should be addressed when preparing for PRFA and NORA in
these frequently at-risk patients. Special attention should be
focused on both cardiovascular and pulmonary comorbidities.
Additionally, the clinician should speciﬁcally inquire about the
current use of anticoagulant medications as these patients may
frequently be prescribed these medications which can vary
signiﬁcantly in terms of their mode of action and potency
with signiﬁcant procedural and hemostatic consequences.
Speciﬁc patient populations may also have speciﬁc organ
function-related embarrassment that should be considered
when developing a given anesthetic prescription. Speciﬁcally,
patients with liver cancer often have associated cirrhosis and
attendant hemostatic disorderswhichwill result in an increased
risk of bleeding. The proceduralist and the anesthesia provider
will need to agree on acceptable values for crucial values, such
as hemoglobin and platelet levels prior to proceeding and
obtain necessary blood products and/or transfuse the patient
prior to undergoing a procedure. Another example of this is
that patients undergoing PRFA for lung tumor may have
decreased pulmonary reserve and frequently are at high risk
for post-procedural pneumothorax and consequently may
require a chest tube following lesion ablation.
More generally, it is important that patients be evaluated
pre-operatively for the presence of risk factors that may con-
tribute to increased rates of respiratory complications. In
addition to the presence of chronic obstructive pulmonary
disease, providers should also assess indices and historical
factors that may be suggestive of obstructive sleep apnea
(OSA) or sleep-disordered breathing. Indices suggestive of
OSA include body mass index (BMI) > 45 kg/m2 and neck
circumference of 40 cm. Other historical ﬁndings suggestive
of OSA or sleep-disordered breathing include daytime som-
nolence and/or regular daytime headaches. This is important
because the presence of OSA and sleep-disordered breathing
may signiﬁcantly increase the risk of adverse respiratory
events both during and following general anesthesia or
MAC. Similarly, obesity (BMI > 30 kg/m2), and especially
morbid obesity with or without OSA, may increase the poten-
tial for airway obstruction even in the setting of mild sedation.
This can become signiﬁcant in patients undergoing MAC for
kidney or lung PRFA where airway rescue maneuvers may
become necessary in the prone position. As a consequence,
the clinician may elect to go ahead and secure the airway prior
to prone positioning to assure procedural safety. Other poten-
tial options may include substantially reducing the depth of
sedation with agents such as ketamine or dexmedetomidine.
Either way, it is important for the clinician to assess the risk
and beneﬁts of any given approach in the setting of NORA for
these types of procedures.
Finally, the clinician should always take an adequate
history and/or examine previous records to determine if air-
way management has been challenging in the past. Further,
the clinician should perform a comprehensive airway exam
prior to sedation or induction of general anesthesia to identify
patients that may have indices such as poor mouth opening,
decreased cervical range of motion, or shortened thyromental
distance suggestive of a difﬁcult airway. This is relevant in
this population, as many of these patients may have airway
issues as a result of their underlying age and disease state
which may affect the clinician’s anesthetic choice and
approach to airway management for PRFA. For example, in
patients that appear to be challenging, the clinician may elect
to avoid dealing with the airway all together and use
a regional technique or they may elect to have video laryngo-
scopy or a ﬂexible ﬁberoptic scope available in cases where
general anesthesia appears most appropriate. In situations
where the airway appears favorable, the clinician may feel
more comfortable using sedation and MAC with a native
airway. In the case of patients undergoing PRFA, there may
be multiple approaches to achieve success, but the clinician
must weigh the risks and beneﬁts of any given technique in
the setting of a given patient and procedure to develop an
optimal approach and anesthetic plan.
Intraprocedural Management of
PRFA
Because many PRFA procedures are performed in remote
locations, the clinician performing anesthesia and sedation
for these procedures should have experience speciﬁc to
NORA to ensure patient comfort and safety. Further, the
clinicianmust be aware of issues related speciﬁcally to various
PRFA procedures in addition to being able to respond to peri-
procedural adverse events and directing other non-anesthesia
providers to assist in the case of such an event (Table 1).
Dovepress Piccioni et al
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NORA generally requires that the all standard monitoring,
airway equipment, anesthetic drugs and any additional resus-
citation equipment be available from the outset of any given
case. Standard monitoring during PRFA should include pulse
oximetry, ECG, non-invasive blood pressure and capnography
for early detection of respiratory problems.4–6 Processed EEG
devices may be useful to avoid excessive sedation but are not
mandatory. In cases of patients with signiﬁcant coronary dis-
ease or other cardiac conditions such as congestive heart fail-
ure, the clinician may want to consider the placement of an
arterial line. Additionally, the availability of a second-
generation supraglottic airway device is mandatory, as they
are a suitable airway rescue device and can allow for both
oxygenation and ventilation in an emergency situation.
Further, they can be used to facilitate tracheal intubation if
necessary. Capnography should always be available and
utilized in patients undergoing general anesthesia.
Additionally, the authors strongly advocate following the
guidelines of the ASA for the utilization of capnography in
all patients receiving sedation and MAC with a native airway.
Finally, sufﬁcient space must be always allocated to the
anesthesiologist and all anesthesia equipment to facilitate rou-
tine and emergent maneuvers. Box 1 summarizes the main
equipment that the authors recommend should be present in an
environment where PRFA procedures are performed.
The prevention of infections is another important issue
regarding PRFA. Performing invasive procedure outside the
operating room is potentially a risk factor for contamination
of the surgical ﬁeld. There is no consensus on the need for
antibiotic prophylaxis before PRFA. The 2018 guidelines on
antibiotic prophylaxis during vascular and interventional radi-
ology procedures edited by the Society of Interventional
Table 1 Anesthesia Techniques and More Frequent Problems to Face During the Different Types of PRFA
PRFA
Location
Patient Positioning Anesthesia Anesthesiology Concerns Most Frequent
Intraoperative
Complications
Liver Supine GA, LA + MAC,
TPVB, TEA
Need for deep breath and apneic pause; acute
pain for subglissonian or near the parietal
peritoneum tumor
Hemorrhage,
pneumothorax, bile duct
injury, colonic perforation
Kidney Lateral, semi-prone,
prone
GA, LA + MAC Difﬁcult airway management in case of
respiratory failure during sedation in prone
position; need for apneic pause; acute pain for
bowel or ureteral injury
Colonic perforation,
ureteral injury,
hemorrhage
Lung Supine, lateral, prone GA, LA + MAC,
TPVB, TEA, ICNB
Coughing, dyspnea, difﬁcult airway
management in case of respiratory failure
during sedation in prone position; need for
apneic pause
Pneumothorax,
hemorrhage
Bone Supine, lateral, prone GA, LA + MAC Difﬁcult airway management in case of
respiratory failure during sedation in prone
position; dyspnea during rib tumor treatment;
pain due to injury of structures near the
ablation site
Pneumothorax, injury of
structures near the
ablation site (liver, bowel,
nerves, vessels)
Pancreas Supine GA ± TEA, LA + MAC Need for deep breath and apneic pause; post-
procedural severe pain
Hemorrhage, duodenal
perforation
Adrenal gland Lateral, semi-prone,
prone
GA, LA + MAC Difﬁcult airway management in case of
respiratory failure during sedation in prone
position; need for apneic pause; arterial
hypertension
Colonic perforation,
hemorrhage
Thyroid Supine GA, LA, LA + MAC Dyspnea, local pain Hematoma, dysphagia,
temporal voice change
Breast Supine GA, LA + MAC Local pain Hematoma
Abbreviations: GA, general anesthesia; LA, local anesthesia; MAC, monitored anesthesia care; TPVB, thoracic paravertebral block; TEA, thoracic epidural anesthesia;
ICNB, intercostal nerve block.
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Radiology recommend routine prophylaxis only for liver
tumor ablation.7 In low-risk patients, the guidelines recom-
mend the administration of iv cefazolin 1–2 g. In patients at
high risk for postoperative infection (eg cirrhosis, diabetes,
history of biliary-enteric anastomosis), several regimens are
proposed: levoﬂoxacin combined with metronidazole, neo-
mycin and erythromycin; ampicillin/sulbactam; vancomycin
or clindamycin with gentamicin. Finally, the guidelines do not
recommend routine antibiotic prophylaxis for patients under-
going renal, lung, adrenal or bone tumor radiofrequency
ablation. Further, to minimize the risk of infection, rigorous
antiseptic handling of loco-regional equipment (eg. needle,
ultrasound probe) and a careful dressing of the surgical ﬁeld
are essential to guarantee an adequate level of asepsis.
At the end of the procedure, patients must be monitored
at least for 30 mins in a properly equipped recovery
location.4 This area is usually included in the interventional
radiology facility and rigorous discharge criteria must be
applied before return (eg. the ALDRETE score).4 If needed,
the patient must be transferred to the post-anesthesia care
unit (PACU) or the intensive care unit (ICU). This evidence
must be properly managed by the anesthesiologist who must
be properly equipped for patient transfer with portable
mechanical ventilator and vital signs monitor. Figure 1 sum-
marizes PRFAworkﬂow from the anesthesiologist's point of
view.
Speciﬁc PRFA Procedures
PRFA for Liver Tumors
Primary and metastatic liver tumors are the most frequent
indications for PRFA. PRFA for hepatocellular carcinoma is
also used as a bridge therapy for liver transplantation.1,8,9 In
many cases, PRFA is reserved for patients deemed not
suitable for surgical resection of the mass secondary to
poor hepatic reserve, advanced cancer stage, severe comor-
bidities or advanced age. PRFA for liver tumor has mortality
and major complication rates reported to be 0.15% and
4.1%, respectively, although this data was pooled from
patients with liver tumors receiving PRFA, microwave abla-
tion, and percutaneous ethanol injection of tumors.10
In most cases, the anesthetic choice for radio frequency
ablation of the liver is dependent on the surgical approach
that is planned. More speciﬁcally, video-laparoscopic
approaches require general anesthesia versus percutaneous
approaches which can be performed with local inﬁltration
and MAC. In general, video-laparoscopic approaches are
typically indicated for the treatment of lesions that may be
difﬁcult to target via percutaneous puncture or the
approach may be utilized when radio frequency ablation
is performed as part of a staging procedure. In certain
situations, general anesthesia may also be necessary for
liver PRFA. Recently, Beerman et al reported their experi-
ence with PRFA of liver lesions performed under general
anesthesia.3 Interestingly, the authors reported the use of
high-frequency jet ventilation as a way of reducing the
Box 1 Minimum Mandatory Anesthesia Equipment for PRFA
Procedures
Airway management equipment:
Oxygen source with ﬂowmeter (preferably wall-mount and with
back-up system)
Nasal cannula (preferable with capnography capability) and non-
rebreather mask
Bag valve mask and oropharyngeal airway
Second-generation supraglottic airway device (several measures)
and equipment for emergent endotracheal intubation
Endotracheal tubes (several measures)
Laryngoscope blades* and stylets
Monitoring system
Pulse oximetry, ECG, non-invasive blood pressure
Capnography probe (recommended)
Temperature probe
Medications
Sedatives (midazolam, propofol, dexmedetomidine, ketamine)
Opioids (fentanyl, remifentanil, morphine)
Neuromuscular blocking agent (succinylcholine, rocuronium,
cisatracurium)
Antagonists (naloxone, ﬂumazenil, neostigmine, sugammadex)
Basic drug for life support (atropine, ephedrine, epinephrine)
Loco-regional equipment (if loco-regional technique planned)
Local anesthetics (lidocaine, mepivacaine, ropivacaine,
levobupivacaine)
Needles for regional anesthesia
Ultrasound machine with proper probe
Other equipment
Suction source and catheters
Gas scavenging system (if inhaled general anesthesia is planned)
Automated infusion pump
Deﬁbrillator with paddles
Note: *The availability of a videolaryngoscope is advisable for patients screened for
borderline predicted difﬁcult intubation, morbidly obese patients and when the
subject position during the procedure may increase the difﬁculty of intubation.
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amplitude of respiratory movements to create near static
conditions of both the upper-abdominal and intrathoracic
organs allowing for greater surgical precision.
Whenever possible though, the percutaneous treatment
approach in combination with local inﬁltration and MAC
is preferred. In most cases, this approach can provide
adequate anesthesia and analgesia with the possibility of
fewer anesthetic-related side effects. Further, in some
cases depending on the location of the lesion, this techni-
que may allow for the patient to cooperate and thereby
facilitate the performance of the procedure via indirect
liver mobilization by ensuring that the patient is able to
take a deep breath and/or hold their breath for a brief
apneic pause at the request of the proceduralist.
When planning the anesthetic for percutaneous liver
RFA, it is important to note that there appear to be three
main sources of pain during the PRFA of liver lesions.
These are the skin puncture, the glissonian capsule, and
the thermal energy transfer. Additionally, this tends to be
more painful when the treated lesion is subglissonian or
near the parietal peritoneum.9 One anesthetic approach is
to provide local anesthesia via inﬁltration at the puncture
site and at the needle tract down to and including the
glissonian capsule using 2% lidocaine.11,12 Following
inﬁltration of the local anesthetic, sedation is provided by
administering one or more of the following: propofol,
midazolam, diazepam, remifentanil or fentanyl.2,13,14
Where available, a target-controlled infusion (TCI) regi-
men can be used to optimize the delivery of propofol and
remifentanil and enhance recovery at the end of the
procedure.15 In situations where this is not available, the
clinician can still provide adequate sedation using patient
feedback and appropriate monitoring.
Currently, this area represents a fertile area of research
with numerous anesthetic prescriptions for PRFA being stu-
died including the use of pethidine as a sole intravenous
anesthetic.11 Additionally, Wu et al have reported the use of
a single dose of intravenous oxycodone 0.1 mg/kg 15 mins
prior to PRFA and compared that to a continuous infusion of
remifentanil during the procedure. Ultimately, they found
that intravenous oxycodone increased both patient satisfac-
tion and pain relief after the procedure.12 It should be noted
that dexmedetomidine was administered as an additional
sedative in both study arms. In another randomized-
controlled trial by Joung et al, the investigators compared
a combination of dexmedetomidine and remifentanil with the
combination of propofol and remifentanil for PRFA.16 In this
trial, the dexmedetomidine and remifentanil combination
provided better respiratory stability deﬁned as a smaller
change in post-procedure PaCO2 via arterial blood gas and
reduced post-procedure opioid consumption when compared
to the propofol/remifentanil arm. More recently, investiga-
tors have proposed using a dezocine–remifentanil combina-
tion and actually found this to be more effective than
a combination of midazolam–remifentanil.17 In summary,
many of these results come from fairly small studies with
high rates of procedural success in different study arms.
Therefore, the clinician should exercise some degree of cau-
tion and not over-interpret the results of these studies, con-
tinuing to apply their expert clinical judgement in developing
an anesthetic prescription for any given patient that takes into
account their experience andwhat is available at their facility.
Table 2 summarizes suggested dosages of sedatives and
opioids commonly used for sedation during PRFA.
Other centers have combined regional anesthesia techni-
ques with MAC to provide anesthesia for these procedures in
patients with liver tumors. In 2009, Wong et al reported the
use of a thoracic paravertebral block (TPVB) for selected
PRFA procedure.18 Two years later, Cheung Ning described
the use of right TPVB for PRFA under propofol-based
sedation.19 In 2014, Piccioni et al described the use of
TPVB as the sole anesthetic in a case series of 12 patients
using only two nerve stimulator-guided injections at the T7
and T9 paravertebral spaces.20 Additionally, Gazzera et al
also reported their experience using ultrasound-guided
TPVB for PRFA.21 Interestingly though, for cases involving
a subcapsular hepatic lesion, they also performed an addi-
tional right cervical phrenic nerve block with 3 mL of
Table 2 Suggested Dosage for Most Used Hypnotics and
Opioids For Sedation During PRFA
Medication Dosage
Hypnotics
Propofol Loading dose: 0.5–1 mg/kg
Maintenance: 1–3 mg/kg/h
TCI effect-site concentration: 2–4 mcg/mL
Midazolam Bolus dose: 0.02–0.1 mg/kg
Dexmedetomidine Loading dose: 1 mcg/kg over 15 mins
Maintenance: 0.1–0.2 mcg/kg/h
Opioids
Remifentanil 0.05–0.15 mcg/kg/min
TCI effect-site concentration: 1–3 ng/mL
Fentanyl Bolus dose: 0.5–1 mcg/kg
Piccioni et al Dovepress
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lidocaine 2% to further improve procedural tolerance. This
trend continues with other recent studies recapitulating that
TPVB appears to be more effective than local anesthesia for
PRFA of liver tumors.22,23 This is likely a result of TPVB
producing a unilateral somatic and sympathetic nerve block-
ade with the local anesthetic spreading to the epidural and
intercostal spaces further extending the analgesic effect
beyond the procedural epoch.24
Thoracic epidural anesthesia (TEA) represents another
regional anesthetic technique that has been adopted by
some groups for PRFA of liver tumors.25,26 Theoretically,
TEA may provide a denser block than local anesthesia
and/or TPVB, but its execution may be associated with
increased risks, as many of these patients may have sig-
niﬁcant in situ coagulopathies from reduced levels of
clotting factors. Further, TEA may lead to an increased
risk of hemodynamic instability.27 While there are no large
studies comparing different anesthetic techniques, the
authors of this review feel there is increasing evidence
that the TPVB may represent the regional anesthetic of
choice for these procedures. Conversely, albeit in the
absence of comparative studies, TEA seems not to give
a real advantage over TPVB for PRFA, especially when
considering its greater invasiveness and relative more
complex management.
In summary, liver PRFA can be managed in many ways
by anesthesiologists. There is no adequate comparative
study to draw conclusions about which is the best techni-
que but the authors suggest to avoid general anesthesia
whenever possible in order to enhance the patients’ recov-
ery and to decrease the need for post-procedural care.
PRFA for Kidney Tumors
Small kidney tumors (≤3 cm) in patients unsuitable for
surgery can be treated with PRFA.1,28,29 Needle localiza-
tion is typically performed under ultrasound guidance,
with CT used for anatomic conﬁrmation. Patients are
usually positioned in the lateral, semi-prone or prone posi-
tion to avoid peritoneal trauma. These are frequently used
in combination with hydrodissection to displace the bowel,
thereby decreasing the risk of injury and minimizing pain.
In patients with tumors near the ureter, a ureteral stent can
also be placed to decrease the risk for injury. Major
sources of pain for these procedures include the ureter
and bowel, especially if they are in proximity to the
cancer, and therefore these issues must be taken into
account in planning an appropriate anesthetic.
Kidney PRFA can be performed under general anesthesia
or local inﬁltration with MAC.30–36 Local inﬁltration is typi-
cally performed with an injection of 5–10 mL of 2% lidocaine
at the skin and through the needle tract used to access the
lesion. In addition to local anesthesia at the site, sedation with
hypnotics such as midazolam or droperidol and/or opioids
such as fentanyl or meperidine can also be used to improve
patient comfort for this procedure.32,33,35 In contrast to this,
Park et al have reported their experience with intravenous
pethidine alone to improve awareness under anesthesia with
the aim of real-time feedback to prevent inadvertent injury to
surrounding structures like the genitofemoral nerve.34
Recently, Kim et al have compared the efﬁcacy of MAC
with midazolam and fentanyl administration to general
anesthesia for kidney PRFA.36 Interestingly, they found both
better local tumor control and 3-year recurrence-free survival
rates in patients treated under GAwhen compared to patients
receiving MAC. While the etiology of this remains unclear,
the authors have theorized that better pain relief during general
anesthesia resulted in increased time of PRFA treatment with
patients in the general anesthesia group undergoing a median
treatment time of 25 vs 16 mins in those receiving MAC (p <
0.001). Additionally, the authors theorize that there is greater
precision in targeting the tumor under general anesthesia as
a result of controlled respiratory pauses. Ultimately though,
these ﬁndings must be evaluated with some caution given the
retrospective study design and the small sample size, with 10
patients in the MAC group versus 41 patients in the general
anesthesia group.
Thus, general anesthesia is probably the safest
approach for patients at high risk of respiratory failure or
complex procedure when performed in the semi-prone or
prone position. Also, the feasibility of kidney PRFA under
local anesthesia and MAC is widely proven, and this
approach can be adopted on a case-by-case basis, espe-
cially for procedures performed in lateral position.
PRFA for Lung Tumors
PRFA for lung tumors is mainly performed to treat early-
stage non-small cell lung cancer (NSCLC) in high-risk
patients not suitable for surgery.1,37 In these cases, PRFA is
often combined with radiotherapy and chemotherapy and is
performed under CT guidance. Other indications for lung
PRFA include the treatment of small metastatic lung lesions
and palliative treatment of large tumors causing symptoms
such as pain and intractable cough.38 Mortality and major
complications are quite low after PRFA for lung masses,
0.4% and 8–12%, respectively.39,40 Not surprisingly,
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pneumothorax is the most common complication after lung
PRFA (20–25%),1,3 with a post-operative chest tube insertion
rate between 4 and 16%.41,42 The main sources of pain are
the puncture site, the pleura, and in some cases the dia-
phragm. Depending on the location of the tumor, the patient
is positioned in the supine, prone or lateral position.
Historically, general anesthesia has been the anesthetic of
choice for these procedures in most cases because general
anesthesia provides the most controlled conditions under
which the procedure can be performed. General anesthesia
is frequently chosen as it results in reduced patient move-
ment. During this procedure the incidence of coughing can be
signiﬁcant, as a result of the movement of the radio fre-
quency needle, and/or the thermal stimulus, especially
when the radio frequency needle is near bronchial structures,
or lastly as a result of a new pneumothorax.42,43
MAC with local inﬁltration can be used to provide
anesthesia for these procedures but is a second choice when
compared to general anesthesia for the reasons of coughing
and patient movement highlighted above.3,43 At this time,
there are several case series of lung PRFA successfully
performed under and MAC and local inﬁltration using mid-
azolam or propofol in combination with fentanyl or
remifentanil.44–46 Further, Hoffman has published a small
retrospective study comparing MAC and local inﬁltration
with general anesthesia for lung PRFA which found no
difference with regard to PRFA success or patient
complications.46 Based on these ﬁndings, it may be reason-
able in certain situations to consider MAC with local inﬁltra-
tion for this procedure but careful patient selection is likely to
contribute substantially to procedural success.
The adoption of regional anesthetic techniques as the
primary anesthetic for lung PRFA is not widespread at this
time, although some authors have suggested its use to
enhance post-procedural analgesia. Yasui et al have reported
the use of thoracic epidural anesthesia for patients with
tumors located beneath the pleura undergoing PRFA.47
Recently, Ruscio et al also have published a case report
describing the use of TPVB for post-operative analgesia
after PRFA treatment of a left lower lobe tumor.48
Additionally, intercostal nerve blocks and TPVBs have
been performed for post-procedure analgesia for PRFA of
lung tumors associated with rib ablation, reported by
vanSonnenberg et al.49
In summary, general anesthesia appears to be the anes-
thetic technique of choice for patients undergoing PRFA of
lung tumors with some authors investigating the possibility
of certain regional techniques to reduce post-procedural pain.
Based on the authors’ personal experience, MAC with local
inﬁltration is an effective approach but the anesthesiologist
must pay close attention to the respiratory function and
always be ready to assist the patient with a facial mask and,
if necessary, with supraglottic device insertion or tracheal
intubation. Clearly more prospective study is necessary to
clarify the potential role and risk-beneﬁt ratio of regional
anesthesia for patients undergoing this procedure.
PRFA for Bone Tumors
PRFA is commonly used for the treatment of osteoid osteo-
mas and may represent another option for the treatment of
metastatic bone disease, although this remains investiga-
tional at this time.1,50,51 It is well known that the presence
of bone metastasis usually worsens a patient’s quality of life
as a result of signiﬁcant pain and the occurrence of patho-
logic fractures. In some cases, PRFA may now be used as
an alternative to palliative radiotherapy and can further be
combined with medical therapy to reduce patient suffering.
This is supported by the work of several groups who have
reported the efﬁcacy of PRFA in reducing both pain and
consumption of analgesics after treatment of bone
metastasis.52–55 Depending on the stiffness of the tumor
tissue, straight or expandable RFA needles are used. In the
case of a large lesion, usually >3–4 cm, multiple electrode
placements may be necessary. Furthermore, because the
procedure can involve different areas such as the chest
wall, spine, pelvis, and extremities, patient positioning can
vary greatly and sedation may be necessary to allow patient
tolerance of a given position. Bone PRFA can be performed
under general anesthesia or under MAC.52–56 Usually local
inﬁltration with 2% lidocaine is provided intradermally and
around the periosteum. Sedation is most commonly per-
formed with benzodiazepines such as midazolam or broma-
zepam and opioids such as pethidine or fentanyl.54–56
Theoretically, anesthesia for bone PRFA could be provided
under regional anesthesia alone, especially when performed
on an extremity but currently, there is a lack of available
literature, case based or otherwise, on which to base any
recommendations. Thacker et al have reported the use of
combined general and regional anesthesia in a small case
series but at this time there are no large prospective studies
to guide best practices.57
Other Application of PRFA for Tumor
PRFA can also be used to treat many other solid primary
or metastatic tumors involving the pancreas, adrenal gland,
thyroid, and breast.3,58–64 Pancreas, adrenal gland and
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thyroid PRFA are usually performed under local inﬁltra-
tion and MAC. Thyroid PRFA can be also performed
under local inﬁltration alone without the aid of sedation
given the shallow depth of the gland and frequent brevity
of the procedure. In fact, this approach has been endorsed
by the Korean Society of Thyroid Radiology in their
recently published guidelines.65 Conversely, breast PRFA
is frequently performed under general anesthesia because
it is often combined with an axillary sentinel lymph node
dissection and excision.62,63 Finally, radio frequency abla-
tion of pancreatic lesions can be associated with signiﬁcant
post-procedural discomfort, with some groups advocating
a combined general/regional approach with a thoracic epi-
dural for this procedure, as the ablation is typically per-
formed using laparoscopic surgery.
Conclusion
In summary, PRFA has become a widely accepted treat-
ment modality for many types of solid tumors. Frequently,
these procedures are performed outside of the operating
room and, as such, require clinicians with some degree of
expertise and experience in performing NORA. The anes-
thetic technique of choice is typically based on the loca-
tion and the type of lesion to be treated and the experience
of the anesthesia provider with these types of procedures.
At this time, there are few large-scale trials to inform best
practices in caring for these patients but, as with many
clinical situations, the clinician must continue to make an
assessment of the patient and further develop an anesthetic
prescription that best balances the risks and beneﬁts of all
related issues for a given patient. Clearly, PRFA and
various anesthetic approaches for these procedures repre-
sent an area for further prospective investigation to
develop best practice guidelines.
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